Liu Michael, Wai Mabel, Nunez James
Michael Liu is the manager of clinical pharmacy services and director of the PGY-1 pharmacy residency program at Lawrence + Memorial Hospital, New London, Connecticut. Mabel Wai is a clinical pharmacist II of cardiothoracic surgery at the Heart & Vascular Center at Yale New Haven Hospital, New Haven, Connecticut. James Nunez is a clinical pharmacist II of cardiology services at Yale New Haven Hospital
Michael Liu is the manager of clinical pharmacy services and director of the PGY-1 pharmacy residency program at Lawrence + Memorial Hospital, New London, Connecticut. Mabel Wai is a clinical pharmacist II of cardiothoracic surgery at the Heart & Vascular Center at Yale New Haven Hospital, New Haven, Connecticut. James Nunez is a clinical pharmacist II of cardiology services at Yale New Haven Hospital.
Crit Care Nurse. 2019 Oct;39(5):51-57. doi: 10.4037/ccn2019849.
Transdermal lidocaine patches have few systemic toxicities and may be useful analgesics in cardiac surgery patients. However, few studies have evaluated their efficacy in the perioperative setting. Objective To compare the efficacy of topical lidocaine 5% patch plus standard care (opioid and nonopioid analgesics) with standard care alone for postthoracotomy or poststernotomy pain in adult patients in a cardiothoracic intensive care unit.
A single-center, retrospective cohort evaluation was conducted from January 2015 through December 2015 in the adult cardiothoracic intensive care unit at a tertiary academic medical center. Cardiac surgery patients with new sternotomies or thoracotomies were included. Patients in the lidocaine group received 1 to 3 topical lidocaine 5% patches near sternotomy and/or thoracotomy sites daily. Patches remained in place for 12 hours daily. Patients in the control group received standard care alone.
The primary outcome was numeric pain rating for sternotomy/thoracotomy sites. Secondary outcomes were cardiothoracic intensive care unit and hospital lengths of stay and total doses of analgesics received. Forty-seven patients were included in the lidocaine group; 44 were included in the control group. Mean visual analogue scores for pain did not differ between groups (lidocaine, 2; control, 1.9; = .58). Lengths of stay were similar for both groups (cardiothoracic intensive care unit: lidocaine, 3.06 days; control, 3.11 days; = .86; hospital: lidocaine, 8.26 days; control, 7.61 days; = .47).
Adjunctive lidocaine 5% patches did not reduce acute pain in postthoracotomy and post-sternotomy patients in the cardiothoracic intensive care unit.
透皮利多卡因贴剂的全身毒性较小,可能对心脏手术患者是有效的镇痛药。然而,很少有研究评估其在围手术期的疗效。目的:比较5%利多卡因贴剂联合标准护理(阿片类和非阿片类镇痛药)与单纯标准护理对心胸重症监护病房成年患者开胸术后或胸骨切开术后疼痛的疗效。
2015年1月至2015年12月在一家三级学术医疗中心的成人心胸重症监护病房进行了一项单中心回顾性队列评估。纳入行新的胸骨切开术或开胸术的心脏手术患者。利多卡因组患者每天在胸骨切开术和/或开胸术部位附近贴1至3片5%利多卡因贴剂。贴剂每天贴12小时。对照组患者仅接受标准护理。
主要结局是胸骨切开术/开胸术部位的数字疼痛评分。次要结局是心胸重症监护病房和住院时间以及所接受镇痛药的总剂量。利多卡因组纳入47例患者;对照组纳入44例患者。两组间疼痛的平均视觉模拟评分无差异(利多卡因组,2分;对照组,1.9分;P = 0.58)。两组住院时间相似(心胸重症监护病房:利多卡因组,3.06天;对照组,3.11天;P = 0.86;医院:利多卡因组,8.26天;对照组,7.61天;P = 0.47)。
在心胸重症监护病房,辅助使用5%利多卡因贴剂并未减轻开胸术后和胸骨切开术后患者的急性疼痛。